Sign in to view content

Evaluation of Baseline Characteristics on Lesion Progression in a Large Phase 2 Clinical Trial for Geographic Atrophy (FILLY Study)

Eleonora Lad, MD, PhD

Video
Published 2019

Eleonora Lad

AMD Non-neovascular Symposium

Related

ReCLAIM-2: Phase 2 Trial of Subcutaneous Elamipretide in Patients with Noncentral Geographic Atrophy
Jeffrey S. Heier, MD
Annual Meeting Talks
2022
Preliminary Results from a First-in-human Phase I/II Gene Therapy Study (FOCUS) of Subretinally Delivered GT005, an Investigational AAV2 Vector, in Patients with Geographic Atrophy Secondary to Age-related Macular Degeneration
Jared S. Nielsen, MD, MBA
Updates from the Field
2022
Anti-VEGF Resistant Subretinal Fluid Associated With Reduced Risk of Macular Atrophy and Better Vision: Drug-Induced Choroidal New Vessel Homeostasis?
Marco A. Zarbin, MD, PhD
Annual Meeting Talks
2020

Category: AMD-Non-Neovascular

See more